UK Markets close in 3 hrs 43 mins

Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
71.38-0.35 (-0.49%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close71.73
Bid71.25 x 900
Ask71.70 x 1200
Day's range71.09 - 72.18
52-week range56.56 - 73.34
Avg. volume6,144,230
Market cap89.523B
Beta (5Y monthly)0.41
PE ratio (TTM)297.42
Earnings dateN/A
Forward dividend & yield2.84 (3.96%)
Ex-dividend date14 Sept 2021
1y target estN/A
  • Business Wire

    Veklury® (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients with COVID-19

    FOSTER CITY, Calif., September 22, 2021--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive results from a Phase 3 randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of a three-day course of Veklury® (remdesivir) for intravenous (IV) use for the treatment of COVID-19 in non-hospitalized patients at high risk for disease progression. This late-breaking data will be presented at the IDWeek 2021 virtual conference.

  • Business Wire

    Gilead to Present Latest Antiviral Research Data Addressing Urgent Global Needs in Infectious Disease at IDWeek 2021

    FOSTER CITY, Calif., September 20, 2021--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new data from the company’s virology research and development programs at the virtual IDWeek 2021 conference, taking place September 29 – October 3. The findings in COVID-19 research, HIV treatment research and HIV prevention research are the latest example of Gilead’s ongoing commitment to help address the evolving COVID-19 pandemic and the needs of people affected by HIV.

  • Business Wire

    New Data Demonstrate Trodelvy® Survival Benefit in Metastatic Triple-Negative Breast Cancer Patients Regardless of Initial HR/HER2 Status

    FOSTER CITY, Calif., September 16, 2021--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from the Phase 3 ASCENT study evaluating Trodelvy® (sacituzumab govitecan-hziy) in patients with relapsed or refractory metastatic triple-negative breast cancer (TNBC) who received two or more prior systemic therapies, at least one of them for metastatic disease. In a retrospective subgroup analysis, Trodelvy improved progression-free survival (PFS), overall survival (OS) and objective response